Krystal Biotech reports KB113 lesion regression in Gorlin syndrome study
Krystal Biotech reported preliminary results from a three-patient Gorlin syndrome pilot study of investigational immunotherapy KB113. The company said 69 of 83 assessed basal cell carcinoma lesions showed clinical regression, or approximately 83%, after the final evaluation. Biopsies from three selected lesions confirmed complete histological responses, and Krystal Biotech has started discussions with the FDA on further development.
Why it matters
The findings give Krystal Biotech a basis for discussions with the FDA about advancing KB113. The small, preliminary study does not establish the treatment’s broader efficacy, durability, or safety, so larger studies will be needed.
Key facts
- 1The pilot study enrolled three adult patients with Gorlin syndrome. finance.yahoo.com
- 2At the final assessment, 69 of 83 assessed lesions showed some degree of clinical regression. finance.yahoo.com
- 3A total of 42 lesions showed regression greater than 50%. finance.yahoo.com
- 4Eight lesions achieved regression of at least 90%. finance.yahoo.com
- 5Biopsies of three selected treated lesions confirmed complete histological responses. finance.yahoo.com
- 6Krystal Biotech initiated discussions with the US Food and Drug Administration about further KB113 development. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.